Inventor · disambiguated record
Sebastien Andre Campos
Also filed as: CAMPOS SEBASTIEN · CAMPOS SEBASTIEN ANDRE
8 granted patents·11 pending applications·53 citations·filing 2005–2024
84Inventor score
Files withBAMBOROUGH PAUL5GLAXOSMITHKLINE IP DEV LTD5UNIV YALE3NIMBUS CLOTHO INC2QILU PHARMACEUTICAL CO LTD2
Top patents by PatentIndex Score
19 records- 0191US10730862B2Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligaseUNIV YALE·Filed 2013·Granted Aug 4, 2020·15 cites·14 claims
- 0289US9988376B2Benzothiophene derivatives as estrogen receptor inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2014·Granted Jun 5, 2018·9 cites·21 claims
- 0387US9993514B2CompoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2014·Granted Jun 12, 2018·11 cites·12 claims
- 0484US8575181B2Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseasesCAMPOS SEBASTIEN ANDRE·Filed 2009·Granted Nov 5, 2013·13 cites·7 claims
- 0580US7687532B2Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of I.A. rheumatoid arthritisGLAXOSMITHKLINE LLC·Filed 2005·Granted Mar 30, 2010·5 cites·20 claims
- 0674US2024317729A1Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin LigaseUNIV YALE·Filed 2024·Application pending·0 cites
- 0761US10793559B2Chemical compoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2019·Granted Oct 6, 2020·0 cites·3 claims
- 0854US2019127359A1Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin LigaseUNIV YALE·Filed 2018·Application pending·0 cites
- 0953US10457674B2Chemical compoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2017·Granted Oct 29, 2019·0 cites·9 claims
- 1052US2025270200A1Ctps1 inhibitors and uses thereofNIMBUS CLOTHO INC·Filed 2023·Application pending·0 cites
- 1151US2008146606A1Novel compoundsBAMBOROUGH PAUL·Filed 2007·Application pending·0 cites
- 1251US2008176891A1Novel compoundsBAMBOROUGH PAUL·Filed 2007·Application pending·0 cites
- 1351US2010035917A1Pyrrolo[2,3-b]pyridin-4-yl-benzenesulfonamide compounds as 1kk2 inhibitorsBAMBOROUGH PAUL·Filed 2007·Application pending·0 cites
- 1449US2023219986A1Novel aminopyrimidine egfr inhibitorQILU PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 1549US2024034743A9Tricyclic compounds as egfr inhibitorsQILU PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 1646US12331046B2CTPS1 inhibitors and uses thereofNIMBUS CLOTHO INC·Filed 2021·Granted Jun 17, 2025·0 cites·10 claims
- 1741US2010179139A1Pyrrolopyridine compounds, process for their preparation, and their use as medicamentsBAMBOROUGH PAUL·Filed 2008·Application pending·0 cites
- 1838US2019161480A1Chemical CompoundsGLAXOSMITHKLINE IP DEV LTD·Filed 2017·Application pending·0 cites
- 1935US2009023725A1Fused Heteroaryl Derivatives for Use as P38 Kinase InhibitorsBAMBOROUGH PAUL·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →